dc.creatorKorf, Hannelie
dc.creatorBreser, Maria Laura
dc.creatorVan Hoeck, Jelter
dc.creatorGodoy, Gloria Janet
dc.creatorCook, Dana P.
dc.creatorStijlemans, Benoit
dc.creatorDe Smidt, Elien
dc.creatorMoyson, Carolien
dc.creatorCunha, João Paulo Monteiro Carvalho Mori
dc.creatorRivero, Virginia Elena
dc.creatorGysemans, Conny
dc.creatorMathieu, Chantal
dc.date.accessioned2018-06-29T17:05:46Z
dc.date.available2018-06-29T17:05:46Z
dc.date.created2018-06-29T17:05:46Z
dc.date.issued2017-11-02
dc.identifierKorf, Hannelie; Breser, Maria Laura; Van Hoeck, Jelter; Godoy, Gloria Janet; Cook, Dana P.; et al.; MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset; Public Library of Science; Plos One; 12; 11; 2-11-2017; e0187455-e0187455
dc.identifier1932-6203
dc.identifierhttp://hdl.handle.net/11336/50666
dc.identifierCONICET Digital
dc.identifierCONICET
dc.description.abstractMacrophages contribute in the initiation and progression of insulitis during type 1 diabetes (T1D). However, the mechanisms governing their recruitment into the islets as well as the manner of retention and activation are incompletely understood. Here, we investigated a role for macrophage migration inhibitory factor (MIF) and its transmembrane receptor, CD74, in the progression of T1D. Our data indicated elevated MIF concentrations especially in long-standing T1D patients and mice. Additionally, NOD mice featured increased MIF gene expression and CD74+ leukocyte frequencies in the pancreas. We identified F4/80+ macrophages as the main immune cells in the pancreas expressing CD74 and showed that MIF antagonism of NOD macrophages prevented their activation-induced cytokine production. The physiological importance was highlighted by the fact that inhibition of MIF delayed the onset of autoimmune diabetes in two different diabetogenic T cell transfer models. Mechanistically, macrophages pre-conditioned with the MIF inhibitor featured a refractory capacity to trigger T cell activation by keeping them in a naïve state. This study underlines a possible role for MIF/CD74 signaling pathways in promoting macrophage-mediated inflammation in T1D. As therapies directed at the MIF/CD74 pathway are in clinical development, new opportunities may be proposed for arresting T1D progression.
dc.languageeng
dc.publisherPublic Library of Science
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187455
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1371/journal.pone.0187455
dc.rightshttps://creativecommons.org/licenses/by/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiabetes
dc.subjectMif
dc.titleMIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución